Opioid Receptor, mu OPRM1, 1 Variant
Also known as: OPRM1
Use
The Opioid Receptor, mu OPRM1, 1 Variant test is used for pretherapeutic identification of individuals who may require different doses of opioid drugs to achieve effective pain control. It can also help optimize naltrexone treatment for alcohol and opioid dependency. The OPRM1 c.118A>G variant has been associated with varying sensitivity to opioid receptor agonists and antagonists, impacting clinical responses to drugs like morphine and naltrexone.
Special Instructions
Counseling and informed consent are recommended for genetic testing. For New York clients, informed consent is required with submission. The test has been developed and its performance characteristics determined by ARUP Laboratories as a Laboratory Developed Test (LDT). Not cleared or approved by the FDA.
Limitations
The test only detects the targeted OPRM1 mutation, c.118A>G. Diagnostic errors may occur due to rare sequence variations. The test does not replace clinical or therapeutic monitoring and results may be affected by genetic and non-genetic factors not detected by this test.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 66746-9
- 94415-7
- 81259-4
- 50398-7
- 11526-1
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B)
Storage Instructions
Preferred transport temp: Refrigerated.
Causes for Rejection
Plasma or serum. Heparinized specimens. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |